<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025878</url>
  </required_header>
  <id_info>
    <org_study_id>H18-03615</org_study_id>
    <nct_id>NCT05025878</nct_id>
  </id_info>
  <brief_title>13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.</brief_title>
  <acronym>iMETABO</acronym>
  <official_title>Metabolic Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Van Andel Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Victoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the metabolism of cells in the ascites tumour&#xD;
      microenvironment of ovarian cancer patients. This observational study involves intravenous&#xD;
      infusion of [U-13C]glucose into patients during standard paracentesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants and Location:&#xD;
&#xD;
      This study will recruit up to 10 patients of at least 18 years of age with ascites due to&#xD;
      diagnosed ovarian cancer. Eligible study patients will be screened and recruited at BC Cancer&#xD;
      - Victoria. Paracentesis procedure and patient consent will occur at the Island Health -&#xD;
      Royal Jubilee Hospital.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Participants meeting the inclusion criteria will be fitted with a continuous glucose monitor&#xD;
      (FreeStyle Libre) before proceeding to their scheduled appointment for paracentesis. Labeled&#xD;
      glucose will be administered via I.V. at dose of 8g of labeled glucose in 60 mL over 10 min.&#xD;
      This is followed by 4g of labeled glucose in 30 mL over an hour.&#xD;
&#xD;
      Sample collection and processing:&#xD;
&#xD;
      During [U-13C]glucose infusions, the ascites specimens will kept on ice. Samples will be&#xD;
      collected and analyzed by flow cytometry and mass spectrometry for states of metabolism and&#xD;
      metabolite profiles respectively. The ascites fluid will be monitored for changes in&#xD;
      metabolite levels.&#xD;
&#xD;
      [U-13C]glucose Product Information:&#xD;
&#xD;
      [U-13C]glucose clinical grade will be compound BC Cancer Pharmacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Achieve [U-13C]Glucose enrichment in the ascites of ovarian cancer patients</measure>
    <time_frame>Duration of ascites paracentesis (samples collected hourly, up to 5 hours)</time_frame>
    <description>Extracellular [U-13C]Glucose label enrichment in the ascites fluid (measured by mass spectrometry).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare glucose uptake and metabolic pathways in different cell populations in the ascites.</measure>
    <time_frame>Duration of ascites paracentesis (samples collected hourly, up to 5 hours)</time_frame>
    <description>Fractional enrichment of intracellular [U-13C]Glucose and 13C labeled metabolites in T cells, myeloid cells and tumour cells (measured by mass spectrometry).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlate metabolic profiles with functionality of T cells found in the ascites.</measure>
    <time_frame>One time - Duration of ascites paracentesis</time_frame>
    <description>Multi-parametric flow cytometry analysis of glucose uptake, mitochondrial function, T cell phenotypes and function.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>[U-13C]glucose</arm_group_label>
    <description>All participants consented to the study will receive the [U-13C]glucose infusion and collection of ascites for research.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>[U-13C]Glucose</intervention_name>
    <description>Patients are intravenously infused with 28g of [U-13C]glucose over a 5 hour period. Briefly, [U-13C]glucose will be provided by intravenous line containing 8g of [U-13C]glucose in 60 mL over 10 min. After 10 minutes, 4g of [U-13C]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.</description>
    <arm_group_label>[U-13C]glucose</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults over the age of 18 with ascites due to diagnosed ovarian cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ovarian cancer&#xD;
&#xD;
          -  Any stage or grade of disease&#xD;
&#xD;
          -  Ascites fluid that requires draining&#xD;
&#xD;
          -  Any treatment regimen&#xD;
&#xD;
          -  Primary or recurrent ascites&#xD;
&#xD;
          -  Understands the concept of the study and give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have diabetes or abnormal hemoglobin A1C levels.&#xD;
&#xD;
          -  The patient's glucose levels must be between 4 - 11.1 mM before administering an&#xD;
             infusion. This is to ensure that patients are within normal blood glucose levels, as&#xD;
             described by Diabetes Canada.&#xD;
&#xD;
          -  Participants cannot receive chemotherapy treatment during the 5 hour duration of the&#xD;
             experiment as it may compromise the integrity of the data.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julian J. Lum, PhD</last_name>
    <phone>250-519-5700</phone>
    <email>JLum@bccancer.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Rauw, MD</last_name>
    <phone>250-519-5500</phone>
    <email>Jennifer.Rauw@bccancer.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jennifer Rauw</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Rauw, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

